Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 114 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Off-loading Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers

NCT02838784
View directory record Official record
Conditions
Venous Ulcer, Foot Ulcer, Diabetic
Interventions
Artacent Human Amniotic Membrane, Standard of Care
Other · Procedure
Lead sponsor
Tides Medical
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
7
States / cities
Arcadia, California • New Iberia, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 21, 2026, 7:35 AM EDT
Terminated Phase 4 Interventional

RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs

NCT01608776
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
MIST Therapy, SOC - Standard of Care
Device · Other
Lead sponsor
Celleration, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Not applicable Interventional

Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K

NCT02707406
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
NEOX®CORD 1K, standard of care
Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Carlsbad, California • Castro Valley, California • Fair Oaks, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

NCT03446157
View directory record Official record
Conditions
Cancer of the Colon, Colon Cancer, Colon Neoplasms, Colonic Cancer, Neoplasms, Colonic
Interventions
Cetuximab, Palbociclib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 1 Interventional Results available

Biofeedback to Increase Propulsion During Walking After Stroke

NCT02667392
View directory record Official record
Conditions
Stroke
Interventions
Gait Training with Biofeedback, Gait Training with Verbal Feedback
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 21, 2026, 7:35 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis

NCT01478386
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Orthovisc, DonJoy HA lite knee brace, Orthovisc injections and DonJoy HA lite knee brace
Other · Device
Lead sponsor
OAD Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Phase 2 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia

NCT04094090
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Goodman Eye Center
Other
Eligibility
10 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

NCT02783768
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, E-cigarettes
Interventions
E-cigarette, Sham, Hyperpolarized 3-Helium, Gadolinium
Device · Other · Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

NCT01307891
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Cancer
Interventions
Abraxane alone, Abraxane + Tigatuzumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Phase 1 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking

NCT03918408
View directory record Official record
Conditions
Keratoconus, Unstable, Bacterial Keratitis, Ectasia of Cornea
Interventions
PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution
Combination Product
Lead sponsor
Pacific Clear Vision Institute
Other
Eligibility
12 Years to 45 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 21, 2026, 7:35 AM EDT
Not listed Not applicable Interventional

Randomized, Prospective Evaluation of the Toad Brace in Plantar Ulcer Off-loading and Healing

NCT02052817
View directory record Official record
Conditions
Diabetic Foot, Pedal Ulcers
Interventions
Optimal Medical Therapy Debridement + Toad Brace, Optimal Medical Therapy - Debridement
Device · Other
Lead sponsor
Toad Medical Corporation
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Not applicable Interventional Results available

PriMatrix for the Management of Diabetic Foot Ulcers

NCT03010319
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
PriMatrix Dermal Repair Scaffold, Secondary Dressings, Offloading device
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Carlsbad, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 3 Interventional

Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers

NCT01181453
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Dermagraft, Comparator
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

NCT06158828
View directory record Official record
Conditions
AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
Interventions
Rabbit Anti thymocyte globulin, Busulfan, Fludarabine, Thiotepa, Melphalan, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, memory-like natural killer cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, CliniMACS
Drug · Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

NCT02954536
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
pembrolizumab, trastuzumab, capecitabine, cisplatin, Oxaliplatin, 5-Fluorouracil
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 21, 2026, 7:35 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System

NCT04401865
View directory record Official record
Conditions
Corneal Ectasia, Keratoconus, Pellucid Marginal Corneal Degeneration
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Colorado Eye Consultants/Cornea Consultants of Colorado
Industry
Eligibility
8 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Littleton, Colorado • Highland Park, Illinois • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Phase 4 Interventional

Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

NCT07089602
View directory record Official record
Conditions
Diabetic Foot, DFU, Diabetic Foot Ulcer, Foot Ulcer, Diabetic, Ulcer Foot, Venous Leg Ulcer, Leg Ulcer, Leg Ulcers Venous, Ulcer
Interventions
Standard of Care DFU, Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU, Membrane Wrap-Hydro™ DFU, Standard of Care VLU, Tri-Membrane Wrap™ VLU, Membrane Wrap™ VLU, Membrane Wrap-Lite™ VLU, Membrane Wrap-Hydro™ VLU
Other
Lead sponsor
BioLab Holdings
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philidelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 21, 2026, 7:35 AM EDT
Terminated Not applicable Interventional Results available

Anesthesia in Patients With Mitochondrial Disease

NCT02053766
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
Sevoflurane, Dexmedetomidine, Propofol
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 21, 2026, 7:35 AM EDT
Active, not recruiting Phase 3 Interventional

SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)

NCT06140303
View directory record Official record
Conditions
Diabetic Foot
Interventions
SkinTE, Control
Biological · Other
Lead sponsor
PolarityTE
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
23
States / cities
Mesa, Arizona • Castro Valley, California • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Early Phase 1 Interventional

A Targeted Amino Acid Supplement for People With Parkinson's Disease

NCT06954662
View directory record Official record
Conditions
Parkinson Disease, Idiopathic
Interventions
Amino acid supplement, Whey Protein Supplement, Isonitrogenous Placebo Supplement
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
55 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)

NCT06507189
View directory record Official record
Conditions
Aging, Aging Well
Interventions
Combined endurance and resistance training
Other
Lead sponsor
Florida Institute for Human and Machine Cognition
Other
Eligibility
60 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Pensacola, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Not applicable Interventional Results available

Peak Plantar Pressures While Wearing a Carbon Fiber Off Loading Orthoses

NCT03618628
View directory record Official record
Conditions
Diabetes Mellitus, Peripheral Neuropathy, Orthotic Device
Interventions
Carbon Fiber Off Loading Orthosis (CFO)
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Not applicable Interventional

A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AC

NCT06511596
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
BR-AC, Standard Care
Other
Lead sponsor
BioStem Technologies
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
11
States / cities
San Francisco, California • Sylmar, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 21, 2026, 7:35 AM EDT